Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Effect of Platelet Inhibition and / or Lipid Lowering in Non-ACS-patients With Positive Troponin

First Posted Date
2019-01-29
Last Posted Date
2022-05-24
Lead Sponsor
Dr. med. Mahir Karakas
Target Recruit Count
68
Registration Number
NCT03820466
Locations
🇩🇪

University of Leipzig, Leipzig, Germany

🇩🇪

University of Berlin, Campus Benjamin-Franklin, Berlin, Germany

🇩🇪

University Heart Center Hamburg, Hamburg, Germany

and more 4 locations

Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2019-01-28
Last Posted Date
2024-11-29
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Target Recruit Count
1210
Registration Number
NCT03819101
Locations
🇨🇭

Kantonsspital Baden, Baden, Switzerland

🇨🇭

Bellinzona Istituto Oncologico, Bellinzona, Switzerland

🇨🇭

Kantonsspital Baselland, Bruderholz, Switzerland

and more 17 locations

Anticoagulation for Aortic Bioprosthesis (ANTIPRO)

First Posted Date
2019-01-17
Last Posted Date
2022-03-08
Lead Sponsor
Instituto Nacional de Cirugia Cardiaca, Uruguay
Target Recruit Count
140
Registration Number
NCT03807921
Locations
🇺🇾

Instituto Nacional de Cirugia Cardiaca, Montevideo, Uruguay

🇺🇾

Centro Cardiovascular Universitario, Montevideo, Uruguay

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

First Posted Date
2019-01-16
Last Posted Date
2024-07-30
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
18
Registration Number
NCT03805932
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Aspirin to Target Arterial Events in Chronic Kidney Disease

First Posted Date
2019-01-08
Last Posted Date
2023-05-23
Lead Sponsor
University of Southampton
Target Recruit Count
25210
Registration Number
NCT03796156
Locations
🇬🇧

Nottingham Digestive Diseases Centre, Nottingham, United Kingdom

SAPT Versus DAPT in Incomplete Revascularization After CABG

First Posted Date
2018-12-31
Last Posted Date
2022-07-21
Lead Sponsor
Campus Bio-Medico University
Target Recruit Count
800
Registration Number
NCT03789916
Locations
🇮🇹

Università Campus Bio-Medico di Roma, Rome, Italy

A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel

First Posted Date
2018-12-06
Last Posted Date
2023-06-12
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
2366
Registration Number
NCT03766581
Locations
🇺🇸

Temple University Hospital, Philadelphia, Pennsylvania, United States

🇺🇸

Local Institution - 0019, York, Pennsylvania, United States

🇺🇸

Neurology Consultants of Dallas, PA, Dallas, Texas, United States

and more 358 locations
© Copyright 2024. All Rights Reserved by MedPath